hologic , inc . notes to consolidated financial statements ( continued ) ( in thousands , except per share data ) fiscal 2007 acquisition : acquisition of biolucent , inc . on september 18 , 2007 the company completed the acquisition of biolucent , inc . ( 201cbiolucent 201d ) pursuant to a definitive agreement dated june 20 , 2007 . the results of operations for biolucent have been included in the company 2019s consolidated financial statements from the date of acquisition as part of its mammography/breast care business segment . the company has concluded that the acquisition of biolucent does not represent a material business combination and therefore no pro forma financial information has been provided herein . biolucent , previously located in aliso viejo , california , develops , markets and sells mammopad breast cushions to decrease the discomfort associated with mammography . prior to the acquisition , biolucent 2019s primary research and development efforts were directed at its brachytherapy business which was focused on breast cancer therapy . prior to the acquisition , biolucent spun-off its brachytherapy technology and business to the holders of biolucent 2019s outstanding shares of capital stock . as a result , the company only acquired biolucent 2019s mammopad cushion business and related assets . the company invested $ 1000 directly in the spun-off brachytherapy business in exchange for shares of preferred stock issued by the new business . the aggregate purchase price for biolucent was approximately $ 73200 , consisting of approximately $ 6800 in cash and 2314 shares of hologic common stock valued at approximately $ 63200 , debt assumed and paid off of approximately $ 1600 and approximately $ 1600 for acquisition related fees and expenses . the company determined the fair value of the shares issued in connection with the acquisition in accordance with eitf issue no . 99-12 , determination of the measurement date for the market price of acquirer securities issued in a purchase business combination . the acquisition also provides for up to two annual earn-out payments not to exceed $ 15000 in the aggregate based on biolucent 2019s achievement of certain revenue targets . the company has considered the provision of eitf issue no . 95-8 , accounting for contingent consideration paid to the shareholders of an acquired enterprise in a purchase business combination , and concluded that this contingent consideration will represent additional purchase price . as a result , goodwill will be increased by the amount of the additional consideration , if any , when it becomes due and payable . as of september 27 , 2008 , the company has not recorded any amounts for these potential earn-outs . the allocation of the purchase price is based upon estimates of the fair value of assets acquired and liabilities assumed as of september 18 , 2007 . the components and allocation of the purchase price consists of the following approximate amounts: .

Table:
net tangible assets acquired as of september 18 2007 | $ 2800
developed technology and know how | 12300
customer relationship | 17000
trade name | 2800
deferred income tax liabilities net | -9500 ( 9500 )
goodwill | 47800
final purchase price | $ 73200
as part of the purchase price allocation , all intangible assets that were a part of the acquisition were identified and valued .
it was determined that only customer relationship , trade name and developed technology and know-how had separately identifiable values .
the fair value of these intangible assets was determined through the application of the income approach .
customer relationship represents a large customer base that is expected to purchase the disposable mammopad product on a regular basis .
trade name represents the .

Question: what portion of the final purchase price of biolucent is dedicated to goodwill?
Answer: 65.3%
Calculation: divide(47800, 73200)